Management After Acute Gout Episode
After an acute gout attack, do NOT initiate urate-lowering therapy (ULT) if this is the patient's first attack or if they have infrequent attacks (<2 per year); instead, focus on patient education, lifestyle modifications, and screening for comorbidities. 1
Immediate Post-Attack Management
Patient Education (Critical First Step)
Every patient must receive comprehensive education about 2:
- Gout pathophysiology and that it is a curable disease
- The existence of effective treatments
- Associated comorbidities requiring screening
- Principles of self-managing future acute attacks
- The concept of "treat-to-target" with lifelong serum urate control
Studies show that full patient education increases adherence to ULT to 92% at 12 months 2.
Lifestyle Modifications
Counsel patients on 2:
- Weight loss if overweight/obese
- Avoid: alcohol (especially beer and spirits), sugar-sweetened drinks, heavy meals, excessive meat and seafood intake
- Encourage: low-fat dairy products, regular exercise
Comorbidity Screening
Systematically screen for 2:
- Renal impairment
- Coronary heart disease
- Heart failure
- Stroke
- Peripheral arterial disease
- Obesity
- Hyperlipidemia
- Hypertension
- Diabetes
- Smoking status
Decision Point: When to Start Urate-Lowering Therapy
DO NOT Start ULT If:
The rationale: Benefits of long-term ULT (≥12 months) have not been studied in patients with single or infrequent attacks. Many patients will have no or few recurrences over many years 1.
START ULT If Patient Has:
- ≥2 gout attacks per year 1, 2
- Tophi (visible or by imaging) 1
- Chronic kidney disease 1
- Urolithiasis 1
- Chronic arthropathy 2
- Serum uric acid >8 mg/dL (higher risk for recurrence) 1
Initiating Urate-Lowering Therapy (When Indicated)
Pre-Treatment Discussion
Before starting ULT, discuss with patient 1:
- Benefits and harms of therapy
- Costs
- Individual preferences
- Need for concomitant prophylaxis against flares
First-Line ULT: Allopurinol
Start low and titrate up 2:
- Initial dose: 100 mg/day
- Titration: Increase by 100 mg increments every 2-4 weeks
- Target: Serum uric acid <6 mg/dL (360 μmol/L)
- For severe gout (tophi, chronic arthropathy, frequent attacks): Target <5 mg/dL (300 μmol/L) until complete crystal dissolution 2
Important caveat: Do NOT maintain serum uric acid <3 mg/dL long-term 2.
Alternative ULT Options
If allopurinol fails to reach target or is not tolerated 2:
- Switch to febuxostat (40 mg/day, equivalent efficacy to allopurinol 300 mg/day) 1
- Switch to uricosuric agent
- Combine allopurinol with uricosuric
Mandatory Flare Prophylaxis During ULT Initiation
Critical: Start prophylaxis when initiating ULT and continue for at least 6 months 2.
Prophylaxis options 2:
- Colchicine: 0.5-1 mg/day (reduce dose in renal impairment)
- Low-dose NSAID (with proton pump inhibitor if appropriate)
- Low-dose corticosteroid
High-quality evidence shows prophylaxis reduces acute gout attacks during ULT initiation, and continuing >8 weeks is more effective than shorter durations 1.
Monitoring and Long-Term Management
- Monitor serum uric acid regularly and maintain <6 mg/dL lifelong 2
- Titrate ULT dose upward until target achieved 2
- Once crystal dissolution complete in severe gout, can maintain target at <6 mg/dL (may reduce ULT dose) 2
- Patient education on self-medicating future flares at first warning symptoms 2
Common Pitfalls to Avoid
- Starting ULT after first attack: Moderate-quality evidence strongly recommends against this 1
- Not providing prophylaxis when starting ULT: This leads to increased flares in first 6 months and poor adherence 1
- Inadequate ULT dosing: Many patients receive insufficient doses to reach target 2
- Stopping ULT prematurely: This is a lifelong therapy once initiated 2
- Not educating patients: Lack of knowledge is a major barrier to effective treatment 2